Journal article
Prognosis of pediatric ulcerative colitis after infliximab failure: A multicenter registry‐based cohort study
Journal of gastroenterology and hepatology, Vol.39(2), pp.312-318
02/2024
DOI: 10.1111/jgh.16431
PMID: 38058020
Abstract
Background and Aim Even with increasing numbers of biologic agents available for management of ulcerative colitis (UC), infliximab (IFX) retains an important place in treatment of pediatric patients with this disease. As few reports have addressed outcomes in pediatric UC patients who had to discontinue IFX, we examined clinical course and prognosis after IFX failure in pediatric UC. Methods A prospective cohort study of pertinent cases enrolled in the Japanese Pediatric Inflammatory Bowel Disease Registry between 2012 and 2020 was conducted to determine outcomes for pediatric UC patients who received IFX but required its discontinuation during follow‐up (IFX failure). Results Of the 301 pediatric UC patients in the registry, 75 were treated with IFX; in 36 of these, IFX was discontinued during follow‐up. Severity of UC at onset and absence of concomitant immunomodulator therapy were significant risk factors for IFX failure (P = 0.005 and P = 0.02, respectively). The cumulative colectomy rate after IFX failure was 41.3% at 1 year and 47.5% at 2 years. Colectomy was significantly more frequent when IFX was discontinued before June 1, 2018, than when IFX was discontinued later (P = 0.013). This difference likely involves availability of additional biologic agents for treatment of UC beginning in mid‐2018 (P = 0.005). Conclusion In pediatric UC patients, approximately 50% underwent colectomy during a 2‐year interval following IFX failure. Prognosis after IFX failure appeared to improve with availability of new biologic agents and small‐molecule drugs in mid‐2018.
Details
- Title: Subtitle
- Prognosis of pediatric ulcerative colitis after infliximab failure: A multicenter registry‐based cohort study
- Creators
- Ryusuke Nambu - Saitama Children's Medical CenterTakahiro Kudo - Juntendo UniversityNao Tachibana - Tokyo Metropolitan Children's Medical CenterHirotaka Shimizu - National Center For Child Health and DevelopmentTatsuki Mizuochi - Kurume UniversitySawako Kato - Shinshu UniversityMikihiro Inoue - Fujita Health UniversityHideki Kumagai - Jichi Medical UniversityTakashi Ishige - Gunma UniversityReiko Kunisaki - Yokohama City University Medical CenterAtsuko Noguchi - Akita UniversityToshifumi Yodoshi - Okinawa Prefectural Chubu HospitalShin‐Ichiro Hagiwara - Osaka Women's and Children's HospitalShigeo Nishimata - Tokyo Medical UniversityFumihiko Kakuta - Miyagi Children's HospitalTakeshi Saito - Chiba HospitalItaru Iwama - Saitama Children's Medical CenterYuri Hirano - National Center For Child Health and DevelopmentToshiaki Shimizu - Juntendo UniversityKatsuhiro Arai - National Center For Child Health and DevelopmentTomoko Hara - Saitama Children's Medical CenterKeisuke Jimbo - Juntendo UniversityYugo Takaki - Kurume UniversityYoshiko Nakayama - Shinshu University School of MedicineKeiichi Uchida - Mie UniversityKoji Yokoyama - Jichi Medical UniversityTsuyoshi Ogashiwa - Yokohama City University Medical CenterJPIBD‐R network
- Resource Type
- Journal article
- Publication Details
- Journal of gastroenterology and hepatology, Vol.39(2), pp.312-318
- DOI
- 10.1111/jgh.16431
- PMID
- 38058020
- ISSN
- 0815-9319
- eISSN
- 1440-1746
- Number of pages
- 7
- Grant note
- Grant‐in‐Aid for the National Centre for Child Health and Development (2019A‐3) Health and Labour Science Research Grant for Research on Intractable Diseases from the Ministry of Health, Labour, and Welfare of Japan (26‐067)
- Language
- English
- Date published
- 02/2024
- Academic Unit
- Stead Family Department of Pediatrics; Gastroenterology, Hepatology, Pancreatology, and Nutrition
- Record Identifier
- 9985214170002771
Metrics
1 Record Views